Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing
- PMID: 38487723
- PMCID: PMC10938850
- DOI: 10.3389/fonc.2024.1355715
Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing
Abstract
Introduction: Accurate identification and characterization of Large Genomic Rearrangements (LGR), especially duplications, are crucial for precise diagnosis and risk assessment. In this report, we characterized an intragenic duplication breakpoint of PALB2 to determine its pathogenicity significance.
Methods: A 52-year-old female with triple-negative breast cancer was diagnosed with a novel PALB2 LGR. An efficient and accurate methodology was applied, combining long-read sequencing and transcript analysis for the rapid characterization of the duplication.
Results: Duplication of exons 5 and 6 of PALB2 was validated by transcript analysis. Long-read sequencing enabled the localization of breakpoints within Alu elements, providing insights into the mechanism of duplication via non-allelic homologous recombination.
Conclusion: Using our combined methodology, we reclassified the PALB2 duplication as a pathogenic variant. This reclassification suggests a possible causative link between this specific genetic alteration and the aggressive phenotype of the patient.
Keywords: LGR; PALB2; breast cancer; long-read sequencing; molecular alteration.
Copyright © 2024 Ban, Chabert, Guignard, Puechberty, Cabello-Aguilar, Pujol, Vendrell and Solassol.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


References
-
- Loveday C, Garrett A, Law P, Hanks S, Poyastro-Pearson E, Adlard JW, et al. . Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes. Ann Oncol. (2022) 33:1318–27. doi: 10.1016/j.annonc.2022.09.152 - DOI - PubMed
-
- Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer. (2020) 126:549–58. doi: 10.1002/cncr.32572 - DOI - PMC - PubMed
LinkOut - more resources
Miscellaneous